Malignant hypercalcaemia in patients with neuroendocrine tumours. Report of 2 cases of parathyroid hormone-related peptide-secreting pancreatic tumours
Keywords:
Hypercalcaemia, Parathyroid Hormone Related Protein, Pancreatic NeoplasiaAbstract
Parathyroid hormone-related peptide-mediated hypercalcaemia (PTH-rp) is rare in patients with neuroendocrine tumours. The clinical cases are thus presented on two patients with pancreatic neuroendocrine tumours with liver metastases, but without bone involvement and with hypercalcaemia associated with elevated PTH-rp and with PTH suppressed. In both cases, it was possible to temporarily bring the calcium levels back to normal with the use of somatostatin analogues, but during the course of the disease, the addition of bisphosphonates was required in one of them.
With the discussion of these cases and the review of the literature and similar published cases, it is hoped to contribute to provide better knowledge of this disease.
Author Biographies
Luis Felipe Fierro-Maya, Instituto Nacional de Cancerología
Unidad de Endocrinología Oncológica, Instituto Nacional de Cancerología, Bogotá D.C, Colombia
Liliana Mejía-Vidal, Clinicentro Sanitas EPS
Endocrinología, Clinicentro Sanitas EPS, Bogotá D.C, Colombia
Camilo Andrés Quintero-Cadavid, Universidad de Antioquia
Endocrinología, IPS Universitaria León XIII, Universidad de Antioquia, Medellín, Colombia
Mireya Tapiero-García, Instituto Nacional de Cancerología
Unidad de Endocrinología Oncológica, Instituto Nacional de Cancerología, Bogotá D.C, Colombia
References
Srirajaskanthan R, McStay M, Toumpanakis C, Meyer T, Caplin ME. Parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumours: Case series and literature review. Neuroendocrinology. 2009;89:48-55.
https://doi.org/10.1159/000151222
Matsen SL, Yeo CJ, Hruban RH, Choti MA. Hypercalcemia and pancreatic endocrine neoplasia with elevated PTH-rP: Report of two new cases and subject review. J Gastrointest Surg. 2005;9:270-9.
https://doi.org/10.1016/j.gassur.2004.06.012
Kamp K, Feelders RA, van Adrichem RCS, de Rijke YB, van Nederveen FH, Kwekkeboom DJ, et al. Parathyroid Hormone Related Peptide (PTHrP) Secretion by Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Clinical Features, Diagnosis. Management, and Follow-Up. 2015;99:3060-9.
https://doi.org/10.1210/jc.2014-1315
Mundy GR, Edwards JR. PTH-related peptide (PTHrP) in hypercalcemia. J Am Soc Nephrol. 2008;19:672-5.
https://doi.org/10.1681/ASN.2007090981
Hiraki A, Ueoka H, Bessho A, Segawa Y, Takigawa N, Kiura K, et al. Parathyroid hormone-related protein measured at thetime of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia. Cancer. 2002;95:1706-13.
https://doi.org/10.1002/cncr.10828
Salahudeen A, Gupta A, Jones J, Cowan R, Vusirikala M, Kwong C, et al. PTHrP-Induced Refractory Malignant Hypercalcemia in a Patient With Chronic Lymphocytic Leukemia Responding to Denosumab. Clin Lynphoma Myeloma Leuk. 2015;15: e137-40.
https://doi.org/10.1016/j.clml.2015.06.007
Milanesi A, Yu R, Wolin EM. Humoral hypercalcemia of malignancy caused by parathyroid hormone-related peptidesecreting neuroendocrine tumors: Report of six cases. Pancreatology. 2013;13:324-6.
https://doi.org/10.1016/j.pan.2013.02.007
Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707-12.
https://doi.org/10.1097/MPA.0b013e3181ec124e
Milanesi A, Yu R, Geller SA, Burton D, Deftos LJ, Wolin EM. Concurrent primary hyperparathyroidism and humoral hypercalcemia of malignancy in a patient with multiple endocrine neoplasia type 1. Pancreas. 2011;40:634-7.
https://doi.org/10.1097/MPA.0b013e318214f65e
Barakat MT, Ashrafian H, Todd JF, Meeran K, Williams GR. Severe hypercalcaemia from secretion of parathyroid hormone-related peptide. Case report. Lancet Oncol. 2004;5:633-5.
https://doi.org/10.1016/S1470-2045(04)01599-2
Sugishita K, Tanno M, Kijima M, Kamoshita H, Mitamura T, Hayakawa K. Malignant hypercalcemia due to gastric endocrine cell carcinoma. Intern Med. 1995;34:104-7.
https://doi.org/10.2169/internalmedicine.34.104
Zabel M, Dietel M. Endocrine markers in malignant tumor cells producing parathyroid hormone-related protein. Exp Clin Endocrinol. 1993;101:297-302.
https://doi.org/10.1055/s-0029-1211247
Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen H, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19:558-67.
https://doi.org/10.1200/JCO.2001.19.2.558
Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
https://doi.org/10.1016/j.ejca.2008.10.026
Barhoum M, Hutchins L, Fonseca V. Intractable hypercalcemia due to a metastatic carcinoid secreting parathyroid hormonerelated peptide and interleukin-6: response to octreotide. Am J Med Sci. 1999;318:203-5.
https://doi.org/10.1016/S0002-9629(15)40616-0
Clemens P, Gregor M, Lamberts R. Pancreatic neuroendocrine tumor with extensive vascularisation and parathyroid hormone-related protein (PTHrP)-associated hypercalcemia of malignancy. Exp Clin Endocrinol Diabetes. 2001;109: 378-85.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.